14.88
-0.37(-2.43%)
Currency In USD
Address
1560 Trapelo Road
Waltham, MA 02451
United States of America
Phone
781 786 8230
Website
Sector
Healthcare
Industry
Biotechnology
Employees
192
First IPO Date
September 17, 2020
| Name | Title | Pay | Year Born |
| John G. Cox | Chief Executive Officer, President & Director | 1.03M | 1963 |
| Oxana Beskrovnaya | Chief Innovation Officer | 719,521 | 1961 |
| Ranjan Batra | Chief Scientific Officer | 719,521 | N/A |
| Douglas Kerr | Chief Medical Officer | 745,640 | 1967 |
| Johanna Friedl-Naderer | Chief Commercial Officer | 748,769 | 1968 |
| Rajesh Manchanda | Chief Technical Officer | 0 | 1966 |
| Daniel Wilson | Senior VP & Head of Legal | 0 | 1972 |
| Erick J. Lucera | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer and Treasurer | 0 | 1968 |
| James Bilotta | Chief Digital & Information Officer | 0 | N/A |
| Debra Feldman | Chief Regulatory Affairs Officer | 0 | 1971 |
| Lucia Celona | Chief Human Resource Officer | 0 | 1966 |
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
